Forde PM, Rudin CM (2012). «Crizotinib in the treatment of non-small-cell lung cancer». Expert Opin Pharmacother13 (8): 1195-201. PMID22594847. doi:10.1517/14656566.2012.688029.
Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP (2011). «Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)». J. Med. Chem.54 (18): 6342-63. PMID21812414. doi:10.1021/jm2007613.
Janoueix-Lerosey I, Schleiermacher G, Delattre O (2010). «Molecular pathogenesis of peripheral neuroblastic tumors». Oncogene29 (11): 1566-79. PMID20101209. doi:10.1038/onc.2009.518.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G (2007). «Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma». Mol. Cancer Ther.6 (12 Pt 1): 3314-22. PMID18089725. doi:10.1158/1535-7163.MCT-07-0365.
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG (2007). «An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms». Cancer Res.67 (9): 4408-17. PMID17483355. doi:10.1158/0008-5472.CAN-06-4443.
Forde PM, Rudin CM (2012). «Crizotinib in the treatment of non-small-cell lung cancer». Expert Opin Pharmacother13 (8): 1195-201. PMID22594847. doi:10.1517/14656566.2012.688029.
Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP (2011). «Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)». J. Med. Chem.54 (18): 6342-63. PMID21812414. doi:10.1021/jm2007613.
Janoueix-Lerosey I, Schleiermacher G, Delattre O (2010). «Molecular pathogenesis of peripheral neuroblastic tumors». Oncogene29 (11): 1566-79. PMID20101209. doi:10.1038/onc.2009.518.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G (2007). «Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma». Mol. Cancer Ther.6 (12 Pt 1): 3314-22. PMID18089725. doi:10.1158/1535-7163.MCT-07-0365.
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG (2007). «An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms». Cancer Res.67 (9): 4408-17. PMID17483355. doi:10.1158/0008-5472.CAN-06-4443.
